


## Holiday Letter from Our Executive Team

With the holidays upon us, it is time to reflect on what Virica Biotech has accomplished in 2022, thanks to the hard work of our employees and partners.

This year, we **launched the *Virica Advantage***; expanding our scientific team and investing in our powerful high throughput platform. Together, our viral enhancers are now in the hands of many clients and partners. We're proud to say that for almost 30 clients we have **over 50 compound selection projects completed or ongoing**, specifically designed to optimize yields of AAV, LV and other types of viral vectors. We also produced two GMP batches and shipped the first GMP product to a client this year!

In addition to visiting clients' facilities, we were also delighted to get **back to in-person conferences in 2022**. From the *World Vaccine Congress* to *Cell and Gene Meeting on the Mesa*, we've made a lot of connections and built great relationships with viral vector manufacturers and leading research institutions.



**Left to right, Ella Korets-Smith, Ken Newport, Patrick Miron, Jean-Simon Diallo, Paul Casey, Jondaivid De Jong**

We **formed strong partnerships** including with the National Research Council Canada. To paraphrase NRC president, Iain Stewart... *"The NRC's collaboration with Virica ...brings us one step closer to accelerating the development of affordable and accessible ... cell and gene therapies...."*

This was a year for making waves. Virica's CEO, Jean-Simon Diallo, was featured in [Phacilitate](#) and [BioteCanada Insights](#) magazine. We also hosted our first webinar on *Process Intensification in AAV Gene Therapy*. [Register here to access the full webinar.](#)

Our innovative approach to viral enhancers was also recognized when we won: [Best Elevator Pitch award](#) – Bioprocess Modelling of Upstream Viral Vector Production Enhancement at the International Society for Cell & Gene Therapy Conference, (ISCT). [Top Scoring Canadian Abstract](#) – Overcoming Barriers to Viral Vector Production

Looking ahead to 2023, our team is excited to continue to expand our roster of clients and see clients scale their programs with VSEs into production and the clinic. Together, we look forward to helping clients, take that vital step to get better cell and gene therapies to the patients who need it most.

On behalf of everyone at Virica, we'd like to thank our clients, partners, stakeholders and investors for their continued support of our important work.

We wish you and yours a joyful holiday season and a prosperous 2023.